BTK and B-cell chronic lymphocytic leukemia: Selinexor is currently in a phase 1 clinical trial for chronic lymphocytic leukaemia (CLL) in combination with the BTK inhibitor ibrutinib and the addition of NK cell adoptive transfer/CAR-NK cells and/or combination with an anti-CD20 antibody may further improve clinical responses (NCT02303392) [102,103].